Home/Filings/3/0000950170-24-037472
3//SEC Filing

ARCH Venture Fund IX, L.P. 3

Accession 0000950170-24-037472

CIK 0001782303other

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 7:50 PM ET

Size

28.6 KB

Accession

0000950170-24-037472

Insider Transaction Report

Form 3
Period: 2024-03-27
Holdings
  • Common Stock

    (indirect: See footnotes)
    27,349
  • Common Stock

    (indirect: See footnotes)
    41,025
  • Series A Convertible Preferred Stock

    (indirect: See footnotes)
    Common Stock (424,908 underlying)
  • Series C Convertible Preferred Stock

    (indirect: See footnotes)
    Common Stock (164,835 underlying)
  • Series A Convertible Preferred Stock

    (indirect: See footnotes)
    Common Stock (454,212 underlying)
  • Series B Convertible Preferred Stock

    (indirect: See footnotes)
    Common Stock (227,920 underlying)
  • Series C Convertible Preferred Stock

    (indirect: See footnotes)
    Common Stock (201,465 underlying)
  • Series C Convertible Preferred Stock

    (indirect: See footnotes)
    Common Stock (366,301 underlying)
  • Series A Convertible Preferred Stock

    (indirect: See footnotes)
    Common Stock (586,080 underlying)
Footnotes (6)
  • [F1]Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
  • [F2]Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
  • [F3]ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
  • [F4]Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
  • [F5]ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein., if any.
  • [F6]Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

Documents

1 file

Issuer

Boundless Bio, Inc.

CIK 0001782303

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001666306

Filing Metadata

Form type
3
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 7:50 PM ET
Size
28.6 KB